http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AU-2019246762-B2

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5053f82a7cd17c60822674b657cfb89e
classificationCPCAdditional http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/Y02A50-30
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-58
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P13-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P9-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4184
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-2095
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-32
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-40
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-6951
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-437
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/B82Y5-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-44
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-12
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P1-18
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-20
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-44
filingDate 2019-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2021-11-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4e13f5514fa42ebfb804c3bcc5c58a4d
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a3739e61d9f77f1c7a5c1e4873ef0440
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_f44b88f795e587053ca53040cb30f49f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5a712982297f3a598cbe859a92ce96a0
publicationDate 2021-11-11-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber AU-2019246762-B2
titleOfInvention Rifaximin complexes
abstract There is provided a complex comprising rifaximin and a complexing agent, wherein the ncomplexing agent is a polyvinyl pyrrolidone (PVP) or a cyclodextrin. There is also n5 provided a process for preparing the complex, a pharmaceutical composition including nthe complex and therapeutic uses of the complex. n11765256_1 (GHMatters) P87152.AU.3
priorityDate 2008-12-10-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2007047253-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-0232459-A2
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9904823-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-3089818-A
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID426098818
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID57507834
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID444041
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID24796
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419582371
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID415712579
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID411809709
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6436173
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID423592648
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6324616

Total number of triples: 46.